Clinical Research Directory

Inclusion Criteria: \- Patients over 18 years of age \- Patients diagnosed with : 1. Non-small cell lung cancer (NSCLC), including adenocarcinoma and squamous cell carcinoma. 2. Head and neck squamous cell carcinoma, p16-negative for oropharyngeal tumors. * Recurrent and/or metastatic tumor not amenable to curative locoregional treatment. * Disease progression under Pembrolizumab immunotherapy, administered at the standard dose of 200 mg every 3 weeks, as first-line treatment for metastatic disease, regardless of the number of cycles received, either as monotherapy or in combination with chemotherapy, as defined below: • For pulmonary adenocarcinomas: i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin or Cisplatin) and Pemetrexed ii. Maintenance therapy with Pembrolizumab, with or without Pemetrexed. • For pulmonary squamous cell carcinomas: i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin) and Paclitaxel +/- ii. Maintenance therapy with Pembrolizumab alone. • For head and neck squamous cell carcinomas : i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin or Cisplatin) ± 5-Fluorouracil (5-FU) or Paclitaxel +/- ii. Maintenance therapy with Pembrolizumab alone. * Eligibility for salvage chemotherapy within standard care: • For pulmonary adenocarcinomas: weekly Paclitaxel, with or without Bevacizumab. * For pulmonary squamous cell carcinomas: Gemcitabine monotherapy. * For head and neck squamous cell carcinomas: weekly Paclitaxel and/or Cetuximab. Standard salvage chemotherapy may be initiated between Day 18 and Day 35 following the last Pembrolizumab injection, at standard doses. * Measurable disease according to RECIST 1.1 criteria. * Performance status (PS) 0 to 2. * Baseline laboratory results meeting the usual criteria permitting initiation of salvage chemotherapy. * Patients who has voluntarily agreed to participate in the study (including additional blood sampling) and has signed the informed consent form. * For the subpopulation with accessible tissue biopsy: * Patient agrees to undergo biopsy, * INR \< 1.5, Platelets \> 50000/μL. * Patients covered by a social security health insurance scheme. Exclusion Criteria: * History of cancer, except for cancers in complete remission for more than 3 years, fully resected cutaneous basal cell carcinomas, or treated carcinoma in situ or cervical intraepithelial neoplasia (in situ cervical epithelioma), * Patients participating in another clinical trial for which an exclusion period is specified, * Minor patients, * For the subpopulation with accessible tissue biopsy, patients receiving: • Clopidogrel (hydrogen sulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) without the possibility of discontinuation for 5 days, • Low-molecular-weight heparin (LMWH) without the possibility of dose suspension prior to the procedure, • Or Fondaparinux without the possibility of discontinuation, • Or Abciximab without the possibility of discontinuation for 24 hours and aPTT \< 50s and ACT \< 150s, • Or Eptifibatide or Tirofiban hydrochloride monohydrate or Argatroban without the possibility of discontinuation 4 hours before the procedure, * Or Bivalirudin without the possibility of discontinuation 2-3 hours before the procedure if CrCL \> 50 mL/min, or 3-5 hours if CrCL \< 50 mL/min, * Or Dabigatran etexilate without the possibility of discontinuation 2-3 days before the procedure if CrCL \> 50 mL/min, or 3-5 days if CrCL \< 50 mL/min. * Vulnerable persons as defined in Articles L1121-5 to L1121-8 : • Pregnant women, women in labour, and breastfeeding mothers, * Persons deprived of liberty by judicial or administrative decision, and persons hospitalized without consent under Articles L3212-1 and L3213-1 who do not fall under the provisions of Article L1121-8, * Persons admitted to a health or social care institution for purposes other than research, * Adults under legal protection measures or unable to express their consent.